Subscribe to RSS

DOI: 10.1055/a-2484-0641
Relationship Between Screening-Detected Atrial Fibrillation and Blood Pressure Levels in Elderly Hypertensive Patients: The OMRON Heart Study
Funding This study was financially supported by OMRON Healthcare Co., Ltd.

Abstract
Background Hypertension is a well-known risk factor for atrial fibrillation (AF) and strokes, but studies assessing screening-detected AF in hypertensive populations and its relationship to the blood pressure (BP) are scarce.
Method We prospectively recruited hypertensive patients (aged ≥60 years) from all over Japan in a decentralized clinical trial. Participants were asked to measure their electrocardiogram (ECG) and BP at home for 3 months with a BP monitor equipped with ECG.
Results Between April 2022 and July 2023, 4,078 hypertensive patients from across the country participated in this study. The mean age was 66.3 ± 5.5 years, and the male proportion was 80.3%. After excluding those with no measurement data (n = 258), AF detection was 5.8% (n = 220/3,820), and the time to AF detection was 3 to 109 days (median 28 days). The mean BP at baseline was 133 ± 14/85 ± 9 mmHg in the morning and 125 ± 14/79 ± 9 mmHg in the evening. AF detection did not significantly differ between the baseline BP categories (log rank test, p = 0.54), with hazard ratios (95% confidence interval) of 0.83 (0.57–1.19), 0.79 (0.55–1.14), and 0.99 (0.59–1.68) for systolic BP (SBP) 135 to 144 and/or diastolic BP (DBP) 85 to 89, SBP 145 to 159 and/or DBP 90 to 99, and SBP ≥ 160 and/or DBP ≥ 100, respectively (SBP ≤ 134 and DBP ≤ 84 as a reference). The results did not change when taking into account the impact of the measurement rates and antihypertensive drugs on AF detection during the observation period.
Conclusion Detection of undiagnosed AF was 5.8% in elderly hypertensives, with no significant differences between the baseline BP categories and no effect of the measurement rate or antihypertensive drugs.
Publication History
Received: 11 June 2024
Accepted: 23 November 2024
Accepted Manuscript online:
25 November 2024
Article published online:
13 December 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Verdecchia P, Reboldi G, Gattobigio R. et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41 (02) 218-223
- 2 Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens 2012; 26 (10) 563-569
- 3 Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, Weert HCPMV. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol 2022; 77 (03) 191-195
- 4 Hermans ANL, Gawalko M, Dohmen L. et al. Mobile health solutions for atrial fibrillation detection and management: a systematic review. Clin Res Cardiol 2022; 111 (05) 479-491
- 5 Senoo K, Miki T, Okura T. et al. Diagnostic value of atrial fibrillation by built-in electrocardiogram technology in a blood pressure monitor. Circ Rep 2020; 2 (07) 345-350
- 6 Senoo K, Yukawa A, Ohkura T. et al. Screening for untreated atrial fibrillation in the elderly population: a community-based study. PLoS One 2022; 17 (06) e0269506
- 7 Senoo K, Yukawa A, Ohkura T. et al. The impact of home electrocardiograph measurement rate on the detection of atrial fibrillation recurrence after ablation: a prospective multicenter observational study. Int J Cardiol Heart Vasc 2023; 44: 101177
- 8 Magnussen C, Niiranen TJ, Ojeda FM. et al; BiomarCaRE Consortium. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation 2017; 136 (17) 1588-1597
- 9 Thomas MC, Dublin S, Kaplan RC. et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21 (10) 1111-1116
- 10 Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119 (16) 2146-2152
- 11 O'Neal WT, Soliman EZ, Qureshi W, Alonso A, Heckbert SR, Herrington D. Sustained pre-hypertensive blood pressure and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. J Am Soc Hypertens 2015; 9 (03) 191-196
- 12 Bacchini M, Bonometti S, Del Zotti F. et al. Opportunistic screening for atrial fibrillation in the pharmacies: a population-based cross-sectional study. High Blood Press Cardiovasc Prev 2019; 26 (04) 339-344
- 13 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
- 14 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
- 15 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138 (17) e426-e483
- 16 Menichelli D, Poli D, Antonucci E, Palareti G, Pignatelli P, Pastori D. START2 Register Investigators. Renin-angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry. Eur J Intern Med 2024; 119: 84-92
- 17 Xing LY, Diederichsen SZ, Højberg S. et al. Systolic blood pressure and effects of screening for atrial fibrillation with long-term continuous monitoring (a LOOP Substudy). Hypertension 2022; 79 (09) 2081-2090